

DLA Piper analysis of CMS formulary files

Medicare Part D Formularies (Table 1)

(PDP and MA-PD combined, excluding SNP, for 30-day supply)

Report on CMS formulary files (January 2025 compared to January 2024). All calculations are percentages, except for co-pay, which is an average dollar amount.

Drugs selected for Medicare Drug Price Negotiation in 2026

Non-specialty drugs, typically with co-pay

	2025	Change vs. 2024	2025	Change vs. 2024	2025	Change vs. 2024	2025	Change vs. 2024
Generic (brand name)/(USP class (USP category))/protected Class	On formulary		Without prior authorization		Tier 3 or lower		Average co-pay	
apixaban (Eliquis)/(blood products (anticoagulants))	100	0	100	0	98	2	\$ 43	\$ 0
dapagliflozin (Farxiga)/(blood glucose regulators (antidiabetic agents))	96	5	100	0	85	3	\$ 37	\$ (4)
empagliflozin (Jardiance)/(blood glucose regulators (antidiabetic agents))	100	1	100	0	100	3	\$ 38	\$ (3)
insulin aspart (Fiasp/Novolog)/(blood glucose regulators (insulins))	66	4	100	0	98	4	\$ 39	\$ (4)
rivaroxaban (Xarelto)/(blood products (anticoagulants))	100	0	100	0	98	1	\$ 44	\$ 1
sacubitril/valsartan (Entresto)/(cardiovascular agents (cardiovascular agents, other))	100	0	100	0	100	1	\$ 42	\$ (1)
sitagliptin phosphate (Januvia)/(blood glucose regulators (antidiabetic agents))	97	2	100	0	100	4	\$ 38	\$ (3)

Specialty drugs, typically with coinsurance

	2025	Change vs. 2024	2025	Change vs. 2024	2025	Change vs. 2024	2025	Change vs. 2024
	On formulary		Without prior authorization		Tier 3 or lower		coinsurance	
etanercept (Enbrel)/(immunological agents (immunosuppressants))	85	-14	2	0	1	0	30	-1
ibrutinib (Imbruvica)/(antineoplastics (molecular target Inhibitor)/protected class)	100	0	2	0	1	0	30	-1
ustekinumab (Stelara)/(immunological agents (immunological agents, other))	100	3	0	0	1	0	30	-1

Commented [KA1]: Can we bring this over to the other page?

DLA Piper analysis of CMS formulary files

Medicare Part D Formularies (Table 1)

(PDP and MA-PD combined, excluding SNP, for 30-day supply)

Report on CMS formulary files (January 2025 compared to January 2024). All calculations are percentages, except for co-pay, which is an average dollar amount.

Drugs selected for Medicare Drug Price Negotiation in 2027

Non-specialty drugs, typically with co-pay	2025	Change vs. 2024	2025	Change vs. 2024	2025	Change vs. 2024	2025	Change vs. 2024
Generic (brand name)/(USP class (USP category))/protected class	On formulary		Without prior authorization		Tier 3 or lower		Average co-pay	
fluticasone/umeclidin/vilanter (Trelegy Ellipta)/(respiratory tract/pulmonary agents (respiratory tract agents, other))	98	2	100	0	100	0	\$ 43	\$ (1)
fluticasone/vilanterol (Breo Ellipta)/(respiratory tract/pulmonary agents (respiratory tract agents, other))	98	0	100	0	100	0	\$ 42	\$ (1)
linacotide (Linzess)/(Gastrointestinal agents (anti-constipation agents))	100	0	100	1	95	30	\$ 46	\$ (14)
linagliptin (Tradjenta)/(blood glucose regulators (antidiabetic agents))	95	-2	100	0	100	4	\$ 39	\$ (2)
semaglutide (Ozempic)/(blood glucose regulators (antidiabetic agents))	98	2	0	-16	96	-2	\$ 42	\$ 0
sitagliptin phos/metformin HCl (Janumet)/(blood glucose regulators (antidiabetic agents))	97	3	100	0	100	4	\$ 42	\$ 0

Formatted: English (United States)

Specialty drugs, typically with coinsurance	2025	Change vs. 2024	2025	Change vs. 2024	2025	Change vs. 2024	2025	Change vs. 2024
	On formulary		Without prior authorization		Tier 3 or lower		coinsurance	
acalabrutinib (Calquence)/(antineoplastics (molecular target inhibitor)/protected class)	100	0	2	0	1	0	30	-1
apremilast (Otezla)/(dermatological agents (dermatological agents, other))	63	-36	0	0	1	0	30	0

DLA Piper analysis of CMS formulary files

Medicare Part D Formularies (Table 1)

(PDP and MA-PD combined, excluding SNP, for 30-day supply)

Report on CMS formulary files (January 2025 compared to January 2024). All calculations are percentages, except for co-pay, which is an average dollar amount.

cariprazine HCl (Vraylar)/(antipsychotics (second generation atypical)/protected class)	100	0	73	7	1	-1	32	-5
deutetrabenazine (Austedo)/(central nervous system (central nervous system agents, other))	88	5	2	0	1	0	29	-1
enzalutamide (Xtandi)/(antineoplastics (antiandrogens)/protected class)	100	0	2	0	1	0	30	-1
nintedanib esylate (Ofev)/(respiratory tract/pulmonary agents (pulmonary fibrosis))	100	0	2	0	1	0	30	-1
palbociclib (Ibrance)/(antineoplastics (molecular target inhibitor)/protected class)	100	0	2	0	1	0	30	-1
pomalidomide (Pomalyst)/(antineoplastics (antiangiogenic)/protected class)	100	0	2	0	1	0	30	-1
rifaximin (Xifaxan)/(antibacterials (antibacterials, other))	100	0	7	-7	9	1	32	0